Tuspetinib

DB15343InvestigationalSmall molecule

Tuspetinib (HM-43239) is under investigation in clinical trial NCT03850574 (Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia).

Mechanism: Pharmacologically active on Receptor-type tyrosine-protein kinase FLT3
Curator reviewed
Formula / weight: C₂₉H₃₃ClN₆ · 501.08 g/mol (avg)
Code names: HM-43239

Resolves to

Compound

UNIIC0WUS7XXE9

Structure

InChIKeyFZLSDZZNPXXBBB-KDURUIRLSA-NSMILESC[C@H]1CN(CC2=CC(=CC(NC3=NC=C(Cl)C(=N3)C3=CNC4=C3C=CC(C)=C4)=C2)C2CC2)C[C@@H](C)N1

Targets

P36888FLT3

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Tuspetinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account